Recursion Pharmaceuticals, Inc. (RXRX) Presents at Jefferies London Healthcare Conference 2025 Transcript

Core Insights - The company is undergoing a leadership transition with Najat Khan taking on the role of CEO, bringing new perspectives and priorities for the next 12 to 18 months [1][2] Group 1: Leadership Transition - Najat Khan has been with the company for 18 months and is familiar with its operations and strategic direction [1] - Chris will assume the role of Chair of the Board, indicating a continuity in leadership [1] Group 2: Strategic Focus - The company plans to concentrate on 2 to 3 key areas moving forward, although specific areas were not detailed in the provided text [2]